Analytical Data
-
Gene name
HLA-A*26:01&B2M Monomer
- Application
-
Alternative Names
HLA-A*2601 & B2M
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AOE46674.1 (G25-W298)&P61769
-
Expression Region
AOE46674.1 (G25-W298)&P61769 (I21-M119)
-
Molecular Weight
39-41 kDa and 10 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-A*26:01 is a class I major histocompatibility complex (MHC) molecule that plays a crucial role in the immune response by presenting peptides to CD8+ T cells. The B2M (beta-2-microglobulin) is an essential component that stabilizes the structure of MHC class I molecules. The study of HLA-A*26:01 and its monomeric form when recombined with B2M is significant for several reasons. Firstly, understanding its structure and function can shed light on the antigen presentation process, which is vital for developing immunotherapies and vaccines. Additionally, specific alleles like HLA-A*26:01 are associated with particular disease susceptibilities and outcomes, including autoimmune diseases and infectious diseases. By producing recombinant HLA-A*26:01&B2M monomers, researchers can investigate the peptide-binding affinity, specificity, and overall stability, which are critical for therapeutic applications. Furthermore, this research can provide insights into population genetics, as different HLA alleles vary across populations, influencing immune responses to diseases. Overall, the characterization of HLA-A*26:01&B2M monomeric proteins is imperative for advancing our understanding of immune mechanisms and enhancing therapeutic approaches in immunology.
